OmniAb (OABI) Q1 2026 Earnings Transcript

OmniAb reported Q1 revenue of $14.4 million, up sharply from $4.2 million a year ago, driven mainly by milestone revenue from partner clinical progress. Management raised 2026 revenue guidance to $28 million-$33 million from an unanticipated milestone, while keeping cash operating expense guidance unchanged at $50 million-$55 million and year-end cash outlook at $33 million-$38 million. The company highlighted continued clinical advancement in OmnidAb and early traction in xPloration and OmniUltra, with 107 active partners and more than $3 billion in contracted milestones.

Analysis

The market is still underestimating how much of this business is becoming an embedded call option on partner execution rather than a pure “tool sales” story. The key second-order effect is that every incremental clinical advance by a partner does three things at once: it creates near-term milestone revenue, raises the probability of future royalty monetization, and validates the underlying platform for the next wave of licensing. That makes the equity less about this quarter’s revenue line and more about compounding optionality across a growing installed base of partnered programs.

The biggest beneficiary of the current setup is the platform economics, not the quarter itself. A modest uplift in royalty-rate quality alongside a still-large contracted milestone pool means the revenue mix can inflect faster than consensus once a handful of late-stage assets read out, but the timing is highly path-dependent. The contrast between strong reported momentum and unchanged cash burn tells us the model is not yet self-funding; until royalties become visible, the stock will trade like a binary catalyst basket rather than a mature royalty company.

The contrarian read is that the market may be overreacting to “AI-enabled discovery” as a narrative while underpricing the more mundane but more durable driver: repeated partner conversion from discovery to clinic. AI is supportive, but the real moat is proprietary biology plus distribution into large pharma R&D budgets. On the other hand, the near-term risk is that milestone revenue remains lumpier than investors want, so any delay in expected clinical events can quickly expose the still-elevated cash burn and push the story back into valuation compression.

Key Decisions for Investors

• Long OABIW on a 3-6 month horizon into the next cluster of clinical readouts; best risk/reward is on weakness, not momentum, because the stock should re-rate on proof of repeated milestone cadence rather than perfect quarterly numbers.
• Pair trade: long OABIW / short a basket of lower-quality preclinical biotech tools names over the next 1-2 quarters; thesis is that validated partner execution and contracted economics will outperform pure narrative AI-discovery exposure.
• Buy TEVA as an indirect beneficiary of the platform’s most visible late-stage catalyst pipeline; use any post-data volatility to add, since positive vitiligo/celiac progress can force upward revisions to perceived asset value over 6-12 months.
• Keep IMVT on a watchlist rather than chasing immediately; the setup improves only if IMVT-1402 shows clear standalone momentum. The near-term knee-jerk overbatoclimab should fade, but there is still execution risk around replacing investor confidence with new clinical data.
• Avoid naked long exposure into catalyst windows unless paired with downside hedges; OABIW’s cash burn means a single delayed milestone or soft partner update can overwhelm the long-term bull case in the next 1-2 quarters.